Clinical trial
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in…
NCT00104975 · Yale University, Other · Completed
Key facts
| NCT number | NCT00104975 |
|---|---|
| Title | Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
| Official title | Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells |
| Lead sponsor | Yale University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological, Drug, Procedure |
| Interventions | alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation |
| Enrollment | 20 |
| Start date | Feb 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Mar 4, 2005 |
| Last update posted | Dec 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: